Skip to main content

Advertisement

SpringerLink
Log in

Comparison of Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation for Treatment of Chronic Myeloid Leukemia

  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

This retrospective study compared outcomes for 81 chronic myeloid leukemia patients who underwent myeloablative or nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT). Sixty-five patients received myeloablative HSCT, and 16 patients received fludarabine (Fd), low-dose busulfan (Bu), and antithymocyte globulin (ATG) in nonmyeloablative HSCT. We determined overall survival (OS) and disease-free survival (DFS), as well as the occurrence of acute and chronic graft-versus-host disease (GVHD).The incidences of acute GVHD of grades II to IV were 14.0% and 18.7% for the myeloablative and nonmyeloablative groups, respectively. The incidence of chronic GVHD was significantly higher in the nonmyeloablative group (80% versus 66%). Five-year OS and DFS rates were significantly higher in nonmyeloablative group (70% for both), compared with 56% and 54%, respectively, for the myeloablative group. A univariate analysis, however, revealed a strong but statistically insignificant trend for enhanced overall OS and DFS in the nonmyeloablative group (P = .1 and .07, respectively). A multivariate analysis with the factors of treatment, age, sex, acute and chronic GVHD, and disease status at the time of transplantation revealed that both OS and DFS were significantly higher in the nonmyeloablative group than in the myeloablative group. These findings suggest that nonmyeloablative Fd/Bu/ATG treatment is at least not inferior (and quite probably superior) in terms of patient outcome compared with standard myeloablative therapy. Further larger-scale randomized clinical trials are warranted to clarify the efficacy of this treatment regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia. Blut. 1962;8:65–66.

    Article  CAS  PubMed  Google Scholar 

  2. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293.

    Article  CAS  PubMed  Google Scholar 

  3. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–172.

    Article  CAS  PubMed  Google Scholar 

  4. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996;17(Suppl 3):S5-S6.

    PubMed  Google Scholar 

  5. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant. 1996;17(Suppl 3):S1-S3.

    PubMed  Google Scholar 

  6. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N EnglJ Med. 2003;348:994–1004.

    Article  Google Scholar 

  7. Guilhot F. Sustained durability of responses plus high rates of cyto-genetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS study [abstract]. Blood. 2004;104:21a.

    Google Scholar 

  8. Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108:1421–1423.

    Article  CAS  PubMed  Google Scholar 

  9. Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108:2332–2338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2005;183–187.

    Article  Google Scholar 

  11. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505.

    Article  PubMed  Google Scholar 

  12. Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. Intern Med. 2002;41:254–264.

    Article  PubMed  Google Scholar 

  13. Copelan EA, Penza SL. Preparative regimens for stem cell transplantation. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 3rd ed. New York, NY: Churchill Livingstone; 1999:1628–1642.

    Google Scholar 

  14. Radich JP, Olavarria E, Apperley JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:685–702, x.

    Article  PubMed  Google Scholar 

  15. Qazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18:703–13, xi.

    Article  PubMed  Google Scholar 

  16. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465.

    PubMed  CAS  Google Scholar 

  17. Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310–2318.

    PubMed  CAS  Google Scholar 

  18. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101:441–445.

    Article  CAS  PubMed  Google Scholar 

  19. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400.

    Article  CAS  PubMed  Google Scholar 

  20. Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol. 2000;27:78–81.

    PubMed  CAS  Google Scholar 

  21. Bornhauser M, Kiehl M, Siegert W, et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol. 2001;115:119–124.

    Article  CAS  PubMed  Google Scholar 

  22. Crawley C, Szydlo R, Lalancette M, et al, for the Chronic Leukemia Working Party of the EBMT. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106:2969–2976.

    Article  CAS  PubMed  Google Scholar 

  23. Sloand EM, Childs RW, Greene A, Phang S, Young LS, Barrett PJ. Non-myeloablative peripheral blood stem cell transplantation for chronic myelogenous leukemia [abstract]. Blood. 2000;96:738a.

    Google Scholar 

  24. Lalancette M, Rezvani K, Szydlo R, et al. Favorable outcome of non-myeloablative stem cell transplant for CML in first chronic phase: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT) [abstract]. Blood. 2000;96:2340a.

    Google Scholar 

  25. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751.

    Article  PubMed  Google Scholar 

  26. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250–259.

    PubMed  CAS  Google Scholar 

  27. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828.

    PubMed  CAS  Google Scholar 

  28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.

    Article  Google Scholar 

  29. Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biol Blood Marrow Transplant. 2006;12:795–807.

    Article  CAS  PubMed  Google Scholar 

  30. Ringdén O, Labopin M, Gluckman E, et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis: Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1996;18:921–929.

    PubMed  Google Scholar 

  31. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073.

    Article  CAS  PubMed  Google Scholar 

  32. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringdén O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood. 2003;101:469–472.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology & Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

    Ming-Huang Chen, Tzeon-Jye Chiou, Peng-Chan Lin, Jyh-Pyng Gau, Hui-Chi Hsu, Liang-Tsai Hsiao, Jin-Hwang Liu & Po-Min Chen

  2. National Yang-Ming University School of Medicine, Taipei, Taiwan

    Ming-Huang Chen, Tzeon-Jye Chiou, Peng-Chan Lin, Jyh-Pyng Gau, Hui-Chi Hsu, Liang-Tsai Hsiao, Jin-Hwang Liu & Po-Min Chen

Authors
  1. Ming-Huang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tzeon-Jye Chiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peng-Chan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jyh-Pyng Gau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui-Chi Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liang-Tsai Hsiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin-Hwang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Po-Min Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tzeon-Jye Chiou.

About this article

Cite this article

Chen, MH., Chiou, TJ., Lin, PC. et al. Comparison of Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation for Treatment of Chronic Myeloid Leukemia. Int J Hematol 86, 275–281 (2007). https://doi.org/10.1532/IJH97.A10701

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1532/IJH97.A10701

Key words

Search

Navigation